14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
VIVS vs ASMB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Assembly Biosciences, Inc (ASMB) is the stronger overall head-to-head candidate over VivoSim Labs, Inc. (VIVS) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VIVS carries a Unified Composite Score of 39.0/100 (SELL) at $0.29 (N/M Forward P/E, -10117.0% operating margin), whereas ASMB carries 31.0/100 (SELL) at $22.50 (N/M Forward P/E, -31.8% operating margin).
Composite vs. Pillar Nuance: While VIVS currently prints a higher short-term Unified Composite Score (39.0/100 SELL vs. ASMB 31.0/100 SELL), ASMB captures the overall institutional head-to-head verdict (6–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-31.8% vs. -10117.0% operating margin) and revenue trajectory (-72.6% vs. -51.4% YoY).
Defensive Composite Rating Caution: Although ASMB compares more favorably head-to-head, both VIVS (39.0/100 SELL) and ASMB (31.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: VIVS is currently in a Breakdown options structure phase (RSI 75.1); meanwhile ASMB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 55.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VIVS vs ASMB. Trailing 12-month operating profitability (VIVS -10117.0% vs ASMB -31.8%) and valuation multiples (VIVS N/M vs ASMB N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $464.6M market capitalization and -31.8% operating margin.
OpEx & R&D Reinvestment31.4% of Rev ($21M)
90D Engineering Disclosures0 Published
Investor FAQ VIVS vs ASMB Key Questions & Quantitative Answers
As of Nov 19, 2026, Assembly Biosciences, Inc (ASMB) is the stronger overall head-to-head candidate over VivoSim Labs, Inc. (VIVS) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). VIVS carries a Unified Composite Score of 39.0/100 (SELL) at $0.29 (N/M Forward P/E, -10117.0% operating margin), whereas ASMB carries 31.0/100 (SELL) at $22.50 (N/M Forward P/E, -31.8% operating margin). Composite vs. Pillar Nuance: While VIVS currently prints a higher short-term Unified Composite Score (39.0/100 SELL vs. ASMB 31.0/100 SELL), ASMB captures the overall institutional head-to-head verdict (6–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-31.8% vs. -10117.0% operating margin) and revenue trajectory (-72.6% vs. -51.4% YoY). Defensive Composite Rating Caution: Although ASMB compares more favorably head-to-head, both VIVS (39.0/100 SELL) and ASMB (31.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: VIVS is currently in a Breakdown options structure phase (RSI 75.1); meanwhile ASMB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 55.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ASMB leads the Growth & Scale pillar: VIVS posts -51.4% YoY revenue growth and +0.0% YoY earnings growth on $112,000 TTM revenue (N/A gross margin, -10117.0% operating margin), compared with ASMB at -72.6% YoY revenue growth and +0.0% YoY earnings growth on $67M TTM revenue (-0.4% gross margin, -31.8% operating margin). On trailing 12-month operating scale, VIVS generates $112,000 in USD-normalized revenue versus $67M for ASMB. In operating R&D and SG&A reinvestment, VIVS deploys N/A (0 90-day corporate R&D disclosures) versus 31.4% of Rev ($21M) (0 disclosures) for ASMB.
ASMB screens cheaper on headline valuation multiples. VIVS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.6x EV/Revenue (unreported EBITDA margin), whereas ASMB trades at N/M Forward P/E, 30.2x Trailing P/E, N/M PEG, and 6.9x EV/Revenue (-31.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VIVS (-343.1% ROE) versus ASMB (-4.6% ROE) capital efficiency.
In options market volatility and institutional positioning, VIVS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.83β · 480% Vol realized risk). By comparison, ASMB carries 109.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.99β · 57% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.